JP2014511348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511348A5 JP2014511348A5 JP2013549892A JP2013549892A JP2014511348A5 JP 2014511348 A5 JP2014511348 A5 JP 2014511348A5 JP 2013549892 A JP2013549892 A JP 2013549892A JP 2013549892 A JP2013549892 A JP 2013549892A JP 2014511348 A5 JP2014511348 A5 JP 2014511348A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cancer
- antibody
- group
- il1rap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434040P | 2011-01-19 | 2011-01-19 | |
| US61/434,040 | 2011-01-19 | ||
| PCT/GB2012/050120 WO2012098407A1 (en) | 2011-01-19 | 2012-01-19 | Anti - il1rap antibodies and their use for treating human |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511348A JP2014511348A (ja) | 2014-05-15 |
| JP2014511348A5 true JP2014511348A5 (enExample) | 2015-03-12 |
| JP5940093B2 JP5940093B2 (ja) | 2016-06-29 |
Family
ID=45755402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549892A Active JP5940093B2 (ja) | 2011-01-19 | 2012-01-19 | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9403906B2 (enExample) |
| EP (3) | EP3508498A1 (enExample) |
| JP (1) | JP5940093B2 (enExample) |
| KR (1) | KR101989134B1 (enExample) |
| CN (2) | CN107929730A (enExample) |
| AU (1) | AU2012208379B2 (enExample) |
| BR (1) | BR112013018399B1 (enExample) |
| CA (1) | CA2824719C (enExample) |
| DK (2) | DK2665749T3 (enExample) |
| ES (2) | ES2714716T3 (enExample) |
| MX (1) | MX354450B (enExample) |
| PL (2) | PL2665749T3 (enExample) |
| RU (1) | RU2597831C2 (enExample) |
| WO (1) | WO2012098407A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009120905A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| CA2828753C (en) | 2011-03-16 | 2022-07-26 | arGEN-X BV | Antibodies to cd70 |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| ES2729057T3 (es) | 2013-12-17 | 2019-10-30 | Aimm Therapeutics Bv | Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) * | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| US11137397B2 (en) | 2014-11-24 | 2021-10-05 | Albert Einstein College Of Medicine | Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| EP3371220A2 (en) * | 2015-11-02 | 2018-09-12 | Janssen Pharmaceutica NV | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
| EP3241845A1 (en) * | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| CN110036028B (zh) | 2016-10-16 | 2023-09-08 | 坎塔吉亚有限责任公司 | 抗il1-rap抗体 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| US10067409B2 (en) | 2017-02-02 | 2018-09-04 | James Harrison Elias | Camera supporting base |
| EP3401332A1 (en) * | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| US11274159B2 (en) | 2017-05-16 | 2022-03-15 | Byondis B.V. | Anti-SIRPα antibodies |
| USD951260S1 (en) | 2017-05-19 | 2022-05-10 | James Harrison Elias | Electronic device mount |
| US11162632B2 (en) | 2017-06-02 | 2021-11-02 | James Harrison Elias | Tripod stabilizing base |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| EP3661558A4 (en) | 2017-08-01 | 2021-08-11 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| BR112021009275A2 (pt) | 2018-11-15 | 2022-01-04 | Byondis Bv | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. |
| USD897414S1 (en) | 2018-11-29 | 2020-09-29 | James Harrison Elias | Tripod mount |
| USD888141S1 (en) | 2018-11-29 | 2020-06-23 | James Harrison Elias | Tripod mount |
| USD888139S1 (en) | 2018-11-29 | 2020-06-23 | James Harrison Elias | Tripod mount |
| USD888815S1 (en) | 2018-11-29 | 2020-06-30 | James Harrison Elias | Tripod mount |
| USD888142S1 (en) | 2018-11-29 | 2020-06-23 | James Harrison Elias | Tripod mount |
| USD896878S1 (en) | 2018-11-29 | 2020-09-22 | James Harrison Elias | Tripod mount |
| USD900201S1 (en) | 2018-11-29 | 2020-10-27 | James Harrison Elias | Tripod mount |
| USD888140S1 (en) | 2018-11-29 | 2020-06-23 | James Harrison Elias | Tripod mount |
| USD896879S1 (en) | 2018-11-30 | 2020-09-22 | James Harrison Elias | Tripod mount |
| USD888817S1 (en) | 2018-11-30 | 2020-06-30 | James Harrison Elias | Tripod mount |
| USD896880S1 (en) | 2018-11-30 | 2020-09-22 | James Harrison Elias | Tripod mount |
| USD888816S1 (en) | 2018-11-30 | 2020-06-30 | James Harrison Elias | Tripod mount |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| BR112021025476A2 (pt) | 2019-06-26 | 2022-10-11 | Glaxosmithkline Ip Dev Ltd | Proteínas de ligação à il1rap |
| EP4013794A4 (en) * | 2019-08-12 | 2023-11-22 | City of Hope | Il1rap antibodies |
| CA3179805A1 (en) * | 2020-04-10 | 2021-10-14 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein |
| JP2023541627A (ja) | 2020-09-14 | 2023-10-03 | イシュノス サイエンシズ ソシエテ アノニム | Ｉｌ１ｒａｐに結合する抗体及びその使用 |
| US11479610B2 (en) | 2020-12-23 | 2022-10-25 | Cantargia Ab | Anti-IL1RAP antibody |
| CN114736885A (zh) * | 2022-05-27 | 2022-07-12 | 四川大学华西医院 | 一种携带bcr-abl1基因激酶区双位点突变的细胞株及其构建方法 |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| AU2024270136A1 (en) | 2023-05-05 | 2025-11-20 | Otsuka Pharmaceutical Co., Ltd. | Anti-il1rap antibodies |
| WO2025027529A1 (en) * | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| GB202402046D0 (en) * | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| WO2025209480A1 (zh) * | 2024-04-02 | 2025-10-09 | 福佑泰生物制药公司 | 抗il1rap抗体以及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5094941A (en) * | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
| CA1329119C (en) * | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
| US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9314623D0 (en) * | 1993-07-14 | 1993-08-25 | Nordion Int Inc | Localization and therapy with agents directed against prostate specific antigen in breast cancer |
| PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CN1169754A (zh) * | 1995-01-23 | 1998-01-07 | 霍夫曼-拉罗奇有限公司 | 人白介素-1受体辅助蛋白 |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US6280955B1 (en) | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| US20030215453A1 (en) | 2002-05-14 | 2003-11-20 | Dedera Douglas A. | Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| AU2002253842A1 (en) | 2000-10-31 | 2002-08-28 | Immunex Corporation | Il-1 receptor accessory protein |
| AU2002324625B2 (en) | 2001-08-07 | 2008-05-08 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| WO2004100987A2 (en) | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| US20080280774A1 (en) | 2005-02-16 | 2008-11-13 | Wyeth | Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
| JP2010507366A (ja) | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−１３受容体α１の抗体アンタゴニスト |
| PT4160212T (pt) | 2008-01-15 | 2024-06-25 | Univ Leland Stanford Junior | Marcadores de células estaminais de leucemia mielóide aguda |
| WO2009120905A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| GB0823445D0 (en) * | 2008-12-23 | 2009-01-28 | Univ Surrey | Biomarker |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) * | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| EP3371220A2 (en) | 2015-11-02 | 2018-09-12 | Janssen Pharmaceutica NV | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
| CN110036028B (zh) | 2016-10-16 | 2023-09-08 | 坎塔吉亚有限责任公司 | 抗il1-rap抗体 |
| WO2018071910A2 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
-
2012
- 2012-01-19 EP EP18205957.6A patent/EP3508498A1/en not_active Withdrawn
- 2012-01-19 DK DK12705387.4T patent/DK2665749T3/en active
- 2012-01-19 EP EP12705387.4A patent/EP2665749B1/en active Active
- 2012-01-19 JP JP2013549892A patent/JP5940093B2/ja active Active
- 2012-01-19 DK DK15197139.7T patent/DK3020730T3/en active
- 2012-01-19 AU AU2012208379A patent/AU2012208379B2/en active Active
- 2012-01-19 PL PL12705387T patent/PL2665749T3/pl unknown
- 2012-01-19 EP EP15197139.7A patent/EP3020730B1/en active Active
- 2012-01-19 CA CA2824719A patent/CA2824719C/en active Active
- 2012-01-19 WO PCT/GB2012/050120 patent/WO2012098407A1/en not_active Ceased
- 2012-01-19 PL PL15197139T patent/PL3020730T3/pl unknown
- 2012-01-19 BR BR112013018399-3A patent/BR112013018399B1/pt active IP Right Grant
- 2012-01-19 ES ES15197139T patent/ES2714716T3/es active Active
- 2012-01-19 RU RU2013138439/10A patent/RU2597831C2/ru active
- 2012-01-19 US US13/979,475 patent/US9403906B2/en active Active
- 2012-01-19 MX MX2013008375A patent/MX354450B/es active IP Right Grant
- 2012-01-19 CN CN201710970452.6A patent/CN107929730A/zh active Pending
- 2012-01-19 KR KR1020137021676A patent/KR101989134B1/ko active Active
- 2012-01-19 CN CN201280014136.7A patent/CN103459424B/zh active Active
- 2012-01-19 ES ES12705387.4T patent/ES2566538T3/es active Active
-
2016
- 2016-06-29 US US15/196,795 patent/US10005841B2/en active Active
-
2018
- 2018-05-24 US US15/988,674 patent/US10995144B2/en active Active
-
2021
- 2021-04-27 US US17/241,609 patent/US11773174B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511348A5 (enExample) | ||
| RU2013138439A (ru) | Анти-il1rap антитела и их применение при лечении людей | |
| ES2686692T3 (es) | Anticuerpo monoclonal anti CD146 | |
| ES2885686T3 (es) | Conjugados anticuerpo-fármaco hidrófilos | |
| JP2025013502A (ja) | 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法 | |
| ES2706428T3 (es) | Inmunoconjugado de IL-12 | |
| Schäfer et al. | Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma | |
| ES2341625T3 (es) | Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas. | |
| ES2289174T3 (es) | Anticuerpos contra el antigeno muc-18. | |
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| Quiles et al. | Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy | |
| JP2005516965A (ja) | 抗ｍｕｃ１８抗体を使用する方法 | |
| JP6738909B2 (ja) | 血液悪性疾患を処置するための低用量抗体に基づく方法 | |
| US10519246B2 (en) | Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis | |
| Goldenberg et al. | Using antibodies to target cancer therapeutics | |
| CA3205707A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| RU2019111303A (ru) | Антитела против edb и конъюгаты антитело-лекарственное средство | |
| AU2022302907A1 (en) | Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap) | |
| CA3196402A1 (en) | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer | |
| Ghani et al. | Antibody fragment and targeted colorectal cancer therapy: A global systematic review | |
| US20200197547A1 (en) | Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers | |
| US20250281654A1 (en) | Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents | |
| Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C | |
| JP2025506485A (ja) | Ｐｅｇ化抗体ヒドロキシル含有薬物複合体 | |
| Eskian et al. | Novel methods to improve the efficiency of radioimmunotherapy for non-Hodgkin lymphoma |